At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 199 enrolled
Drug / intervention
pimavanserin tartrate +1 moredrug
Likely dose
pimavanserin tartrate 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease
In Brief
A Phase 3 clinical trial evaluating pimavanserin tartrate and placebo for Parkinson's Disease Psychosis. Completed, enrolled 199 participants across 63 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease Psychosis
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedAug 2010
Primary CompletionNov 2012
TodayJul 2026
First PostedAug 3, 2010
Enrollment StartJul 1, 2010
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.9 years ago
Interventions
pimavanserin tartratedrug
pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
placebodrug
placebo, tablet, once daily by mouth for 6 weeks